Gabriel Ramírez, Marcelo Vital, Carolina Vergara, Florencia Carusso, Florencia Neffa, Adriana Della Valle, Patricia Esperón
{"title":"CYP2D6基因分型及其对癌症他莫昔芬治疗患者预后的临床影响。","authors":"Gabriel Ramírez, Marcelo Vital, Carolina Vergara, Florencia Carusso, Florencia Neffa, Adriana Della Valle, Patricia Esperón","doi":"10.2217/pme-2023-0063","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aims:</b> To report the distribution of allele frequencies of <i>CYP2D6</i> gene and to evaluate their influence on the clinical outcomes of a group of breast cancer patients receiving adjuvant tamoxifen treatment from Uruguay. <b>Patients & methods:</b> 199 samples were genotyped through real-time polymerase chain reaction assays. Metabolization profiles were inferred from the genotypes. Correlations were evaluated using Pearson's χ<sup>2</sup> test. <b>Results:</b> Phenotype frequencies were 0.65 normal (NM), 0.30 intermediate (IM) and 0.05 poor metabolizers (PM). Similar clinical outcomes between NM and (PM + IM) patient groups (odds ratio = 1.011, 95% CI = 0.2703-3.7826; p = 0.987) were found. <b>Conclusion:</b> CYP2D6 allele frequencies were analyzed for the first time in a cohort from Uruguay. Results did not support any impact of <i>CYP2D6</i> gene polymorphisms on clinical outcomes.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"477-483"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"<i>CYP2D6</i> genotyping and the clinical impact on outcomes in breast cancer tamoxifen-treated patients.\",\"authors\":\"Gabriel Ramírez, Marcelo Vital, Carolina Vergara, Florencia Carusso, Florencia Neffa, Adriana Della Valle, Patricia Esperón\",\"doi\":\"10.2217/pme-2023-0063\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aims:</b> To report the distribution of allele frequencies of <i>CYP2D6</i> gene and to evaluate their influence on the clinical outcomes of a group of breast cancer patients receiving adjuvant tamoxifen treatment from Uruguay. <b>Patients & methods:</b> 199 samples were genotyped through real-time polymerase chain reaction assays. Metabolization profiles were inferred from the genotypes. Correlations were evaluated using Pearson's χ<sup>2</sup> test. <b>Results:</b> Phenotype frequencies were 0.65 normal (NM), 0.30 intermediate (IM) and 0.05 poor metabolizers (PM). Similar clinical outcomes between NM and (PM + IM) patient groups (odds ratio = 1.011, 95% CI = 0.2703-3.7826; p = 0.987) were found. <b>Conclusion:</b> CYP2D6 allele frequencies were analyzed for the first time in a cohort from Uruguay. Results did not support any impact of <i>CYP2D6</i> gene polymorphisms on clinical outcomes.</p>\",\"PeriodicalId\":94167,\"journal\":{\"name\":\"Personalized medicine\",\"volume\":\" \",\"pages\":\"477-483\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Personalized medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/pme-2023-0063\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/11/10 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/pme-2023-0063","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/10 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
CYP2D6 genotyping and the clinical impact on outcomes in breast cancer tamoxifen-treated patients.
Aims: To report the distribution of allele frequencies of CYP2D6 gene and to evaluate their influence on the clinical outcomes of a group of breast cancer patients receiving adjuvant tamoxifen treatment from Uruguay. Patients & methods: 199 samples were genotyped through real-time polymerase chain reaction assays. Metabolization profiles were inferred from the genotypes. Correlations were evaluated using Pearson's χ2 test. Results: Phenotype frequencies were 0.65 normal (NM), 0.30 intermediate (IM) and 0.05 poor metabolizers (PM). Similar clinical outcomes between NM and (PM + IM) patient groups (odds ratio = 1.011, 95% CI = 0.2703-3.7826; p = 0.987) were found. Conclusion: CYP2D6 allele frequencies were analyzed for the first time in a cohort from Uruguay. Results did not support any impact of CYP2D6 gene polymorphisms on clinical outcomes.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
